Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge

被引:55
作者
Bukreyev, Alexander [1 ]
Marzi, Andrea [2 ]
Feldmann, Friederike [2 ]
Zhang, Liqun [4 ]
Yang, Lijuan [1 ]
Ward, Jerrold M. [1 ]
Dorward, David W. [5 ]
Pickles, Raymond J. [4 ]
Murphy, Brian R. [1 ]
Feldmann, Heinz [2 ,3 ]
Collins, Peter L. [1 ]
机构
[1] NIAID, NIH, Bethesda, MD 20892 USA
[2] Canadian Sci Ctr Human & Anim Hlth, Special Pathogens Program, Natl Microbiol Lab, Winnipeg, MB, Canada
[3] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3T 2N2, Canada
[4] Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC USA
[5] NIAID, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA
基金
美国国家卫生研究院;
关键词
Ebola virus; Vaccine; Antibody; Vector; POLARIZED EPITHELIAL-CELLS; VACCINIA VIRUS; RHESUS-MONKEYS; MARBURG VIRUS; HEMAGGLUTININ-NEURAMINIDASE; NEUTRALIZING ANTIBODIES; NUCLEOTIDE-SEQUENCE; ADENOVIRUS VECTORS; ANTI-AD5; IMMUNITY; NONHUMAN-PRIMATES;
D O I
10.1016/j.virol.2008.09.030
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We generated a new live-attenuated vaccine against Ebola virus (EBOV) based on a chimeric virus HPIV3/Delta F-HN/EboGP that contains the EBOV glycoprotein (GP) as the sole transmembrane envelope protein combined with the internal proteins of human parainfluenza virus type 3 (HPIV3). Electron microscopy analysis of the virus particles showed that they have an envelope and surface spikes resembling those of EBOV and a particle size and shape resembling those of HPIV3. When HPIV3/Delta F-HN/EboGP was inoculated via apical surface of an in vitro model of human ciliated airway epithelium, the virus was released from the apical surface; when applied to basolateral surface, the virus infected basolateral cells but did not spread through the tissue. Following intranasal (IN) inoculation of guinea pigs, scattered infected cells were detected in the lungs by immunohistochemistry, but infectious HPIV3/Delta F-HN/EboGP could not be recovered from the lungs, blood, or other tissues. Despite the attenuation, the virus was highly immunogenic, and a single IN dose completely protected the animals against a highly lethal intraperitoneal challenge of guinea pig-adapted EBOV. Published by Elsevier Inc.
引用
收藏
页码:348 / 361
页数:14
相关论文
共 44 条
[1]   Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity [J].
Barouch, DH ;
Pau, MG ;
Custers, JHHV ;
Koudstaal, W ;
Kostense, S ;
Havenga, MJE ;
Truitt, DM ;
Sumida, SM ;
Kishko, MG ;
Arthur, JC ;
Korioth-Schmitz, B ;
Newberg, MH ;
Gorgone, DA ;
Lifton, MA ;
Panicali, DL ;
Nabel, GJ ;
Letvin, NL ;
Goudsmit, J .
JOURNAL OF IMMUNOLOGY, 2004, 172 (10) :6290-6297
[2]   A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge [J].
Bukreyev, A ;
Bukreyev, A ;
Yang, LJ ;
Zaki, SR ;
Shieh, WJ ;
Rollin, PE ;
Murphy, BR ;
Collins, PL ;
Sanchez, A .
JOURNAL OF VIROLOGY, 2006, 80 (05) :2267-2279
[3]   Successful topical respiratory tract immunization of primates against ebola virus [J].
Bukreyev, Alexander ;
Rollin, Pierre E. ;
Tate, Mallory K. ;
Yang, Lijuan ;
Zaki, Sherif R. ;
Shieh, Wun-Ju ;
Murphy, Brian R. ;
Collins, Peter L. ;
Sanchez, Anthony .
JOURNAL OF VIROLOGY, 2007, 81 (12) :6379-6388
[4]   Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene [J].
Casimiro, DR ;
Chen, L ;
Fu, TM ;
Evans, RK ;
Caulfield, MJ ;
Davies, ME ;
Tang, A ;
Chen, MC ;
Huang, LY ;
Harris, V ;
Freed, DC ;
Wilson, KA ;
Dubey, S ;
Zhu, DM ;
Nawrocki, D ;
Mach, H ;
Troutman, R ;
Isopi, L ;
Williams, D ;
Hurni, W ;
Xu, Z ;
Smith, JG ;
Wang, S ;
Liu, X ;
Guan, LM ;
Long, R ;
Trigona, W ;
Heidecker, GJ ;
Perry, HC ;
Persaud, N ;
Toner, TJ ;
Su, Q ;
Liang, XP ;
Youil, R ;
Chastain, M ;
Bell, AJ ;
Volkin, DB ;
Emini, EA ;
Shiver, JW .
JOURNAL OF VIROLOGY, 2003, 77 (11) :6305-6313
[5]   ANTIGENIC VARIATION IN THE HEMAGGLUTININ-NEURAMINIDASE PROTEIN OF HUMAN PARA-INFLUENZA TYPE-3 VIRUS [J].
COELINGH, KLV ;
WINTER, C ;
MURPHY, BR .
VIROLOGY, 1985, 143 (02) :569-582
[6]   Advances in the development of vaccines against Marburg and Ebola viruses [J].
Collins, Peter L. ;
Bukreyev, Alexander .
FUTURE VIROLOGY, 2007, 2 (06) :537-541
[7]  
COLLINS RL, 2007, FIELDS VIROLOGY, V2, P1601
[8]   Pathogenesis of experimental Ebola virus infection in guinea pigs [J].
Connolly, BM ;
Steele, KE ;
Davis, KJ ;
Geisbert, TW ;
Kell, WM ;
Jaax, NK ;
Jahrling, PB .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 :S203-S217
[9]   Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy [J].
Durbin, AP ;
Skiadopoulos, MH ;
McAuliffe, JM ;
Riggs, JM ;
Surman, SR ;
Collins, PL ;
Murphy, BR .
JOURNAL OF VIROLOGY, 2000, 74 (15) :6821-6831
[10]   HUMAN PARA-INFLUENZA TYPE-3 VIRUS HEMAGGLUTININ-NEURAMINIDASE GLYCOPROTEIN - NUCLEOTIDE-SEQUENCE OF MESSENGER-RNA AND LIMITED AMINO-ACID-SEQUENCE OF THE PURIFIED PROTEIN [J].
ELANGO, N ;
COLIGAN, JE ;
JAMBOU, RC ;
VENKATESAN, S .
JOURNAL OF VIROLOGY, 1986, 57 (02) :481-489